For General Information, page-2659

First 2659 Last

Share
Profile

Follow
RYNZN

3,099 Posts.

500

04/09/23

13:02

Post #: 69720175
Share

Originally posted by BoomCrashOffera: ↑

Thanks RYN for drawing my attention to a potential DMD inflammation treatment in very late stage drug development. I’d ALSO like thoughts from those with more medical knowledge, but will outline some thoughts and questions from an initial dive, no guarantee of value-add though.

1. Italfarmaco’s drug, givinostat, has met endpoints in phase 3 trial for DMD. The FDA has accepted their NDA and set a PDUFA date (deadline to complete their review and either approve, deny, or ask for more to be done) of Dec 21, 2023. Italfarmaco used a PRV to get the review date 4 months closer (10 down to 6 mos).

2. Phase 3 trial was on 179 late stage ambulatory boys (mean age 9). I suspect this was to make their primary endpoint testing consistent (time taken to walk up 4 stairs). Apart from no longer being able to walk, I don’t think there is any medical change in inflammation or muscular dystrophy mechanism between ambulatory and non-ambulatory DMD, albeit it (inflammation) is gradually more prevalent as age increases.

Creates two other questions:

(1) If approved, can the treatment be prescribed and reimbursed to non-ambulants as well?

(2) Is there any difference between ambulant and non-ambulant boys as far as private insurer reimbursement goes? I understand US govt reimbursement (Medicaid) is mandatory once FDA approves.

3. ANP left it out of their corporate preso outlining competition. Why? They included other ambulant treatments in development.

4. Givinostat did not get accelerated approval after phase 2. That might be because they targeted ambulant boys.

Expand

I asked the question because this would then sum up our recent discussions of any 'competitors'.

From my understanding Givinostat is less effective than CAP and this may be the reason they were left off the competition slide.

I think CAP has benefit to patients of 3.5 years whilst G only 2.3 years.

this could be a good question though for someone to ask ANP about in Sydney tonight.

ANP Price at posting: 6.3¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

IVZ

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

PAM

PAM secures high-grade Chilean copper play in strong territory

BIO

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

AZL

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

BOE

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

There are more pages in this discussion • 868 more messages in this thread...

First 2659 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 7.5¢		Change 0.000(0.00%)		Mkt cap ! $67.61M

Open	High	Low	Value	Volume
7.3¢	7.5¢	7.1¢	$52.15K	724.6K

Buyers (Bids)

No.	Vol.	Price($)
1	10000	7.1¢

Sellers (Offers)

Price($)	Vol.	No.
7.5¢	8095	1

View Market Depth

No.	Vol.	Price($)
1	10000	0.071
4	34299	0.070
2	28980	0.069
3	33055	0.068
1	9310	0.067

Price($)	Vol.	No.
0.075	8095	1
0.077	50000	1
0.078	75476	2
0.079	175123	2
0.080	287231	3

Last trade - 16.10pm 29/07/2024 (20 minute delay)

PER (ASX) Chart

For General Information, page-2659

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

PAM secures high-grade Chilean copper play in strong territory

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

For General Information, page-2659

Top Stories

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

PAM secures high-grade Chilean copper play in strong territory

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News